Welcome to our dedicated page for Ensign Group SEC filings (Ticker: ENSG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ensign Group鈥檚 dual identity as a post-acute care operator and real-estate lessor makes its SEC disclosures notoriously dense. Medicaid rate shifts, lease covenants, and facility occupancy tables create a maze for analysts who simply want to know, 鈥淗ow is the skilled nursing segment really performing?鈥� Stock Titan eliminates that struggle with AI-powered summaries that turn 300-page documents into crisp insights you can absorb in minutes.
Need the latest Ensign Group quarterly earnings report 10-Q filing? It鈥檚 here, alongside an AI note that highlights reimbursement exposure by state. Curious about Ensign Group insider trading Form 4 transactions or Ensign Group Form 4 insider transactions real-time? Our platform streams them seconds after they hit EDGAR, complete with trend graphs that flag unusual buying by facility leaders. For every 8-K, you鈥檒l see 鈥淓nsign Group 8-K material events explained鈥� so you know exactly why a new lease or acquisition matters. And if you鈥檙e preparing deep research, the Ensign Group annual report 10-K simplified section links directly to AI-generated breakouts of segment margins, census trends, and Standard Bearer rental income.
Investors use these tools to compare quarter-over-quarter revenue, monitor Ensign Group executive stock transactions Form 4, or drill into Ensign Group proxy statement executive compensation without wading through footnotes. With real-time filing alerts, comprehensive coverage of every form, and expert analysis that translates healthcare jargon, understanding Ensign Group SEC documents with AI becomes effortless. Save hours, spot risks early, and act on data instead of digging for it鈥擲tock Titan has already done the heavy lifting.
The Form 144 filing indicates that insider Barry M. Smith intends to sell 700 shares of The Ensign Group, Inc. (ENSG) common stock through Fidelity Brokerage on or about 01 July 2025. The shares are valued at approximately $107,436, implying a per-share price near $153.48. With 57.49 million shares outstanding, the proposed sale represents roughly 0.0012 % of total shares and is therefore immaterial to overall float.
The filing also discloses that the shares were obtained via restricted-stock vesting on 15 Jan 2021 (342 shares) and 15 Apr 2022 (358 shares) as part of compensation packages. Mr. Smith has already sold 2,100 shares in the last three months (04 Apr, 01 May, 02 Jun 2025) for aggregated gross proceeds of $283,577.
- The filer certifies no undisclosed material adverse information and, if applicable, compliance with Rule 10b5-1.
- Given the modest size, the transaction is unlikely to affect liquidity, ownership structure, or valuation metrics, but it does extend a pattern of small monthly insider sales.
The Ensign Group, Inc. (ENSG) filed a Form S-8 with the SEC on June 26, 2025 to register 4,230,804 additional shares of common stock (par $0.001) for issuance under its Amended and Restated 2022 Omnibus Incentive Plan. These shares are in addition to the 3,462,897 shares previously registered on October 26, 2022 (File No. 333-268018), bringing the total registration for the plan to roughly 7.7 million shares. The filing relies on General Instruction E of Form S-8 and incorporates by reference ENSG鈥檚 2024 Form 10-K, its Q1-25 Form 10-Q, and three 2025 Form 8-Ks. Standard Delaware law indemnification provisions, exhibits (plan document, legal opinion, Deloitte consent, etc.), and Form S-8 undertakings are included. No financial results or new strategic transactions are disclosed; the document is strictly an administrative registration to cover future equity-based compensation grants.
Ensign Group (NASDAQ: ENSG) filed a Form 4 disclosing that Vice President & Chief Legal Officer Beverly B. Wittekind executed an option exercise and same-day sale on 18 June 2025 under a Rule 10b5-1 plan adopted 12 Sep 2024.
The officer exercised 4,719 employee stock options at an exercise price of $45.34, acquiring 4,719 common shares. All newly issued shares were immediately sold at $155.00 per share, generating gross proceeds of approximately $0.73 million.
After the sale, Wittekind鈥檚 direct ownership returned to 38,679 shares, unchanged in absolute terms but representing a disposal of roughly 11 % of her previously reported stake. No derivative securities remain outstanding from the exercised grant, which originally vested in five equal installments between 2020 and 2024.
Howard Hughes Holdings Inc. (HHH) 鈥� Form 4 insider activity
Director Anthony Williams reported the grant of 2,094 restricted shares of common stock on 20 June 2025. The award was issued at no cost under the company鈥檚 2020 Equity Incentive Plan and will vest on the earlier of the 2026 annual shareholders鈥� meeting or 1 June 2026. After the transaction, Williams鈥� beneficial ownership increased to 9,202 shares, up from an estimated 7,108 shares. No derivative securities were involved, and the filing contains no open-market purchases or sales.
This appears to be a routine, non-cash compensation grant to a non-employee director and is unlikely to have a material impact on Howard Hughes Holdings鈥� share count, earnings, or governance profile.
FAQ
What is the current stock price of Ensign Group (ENSG)?
What is the market cap of Ensign Group (ENSG)?
What is the primary business model of Ensign Group Inc?
How does Ensign Group Inc generate revenue?
What services are included in Ensign Group Inc's portfolio?
How does the integrated REIT structure benefit the company?
What makes Ensign Group Inc unique in the healthcare industry?
What are the main challenges faced by Ensign Group Inc?
How does the company differentiate itself from other post-acute care providers?
What role do Medicare and Medicaid play in the company鈥檚 revenue model?
